Rapamycin alleviates toxicity of different aggregate-prone proteins

612Citations
Citations of this article
340Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Many neurodegenerative diseases are caused by intracellular, aggregate-prone proteins, including polyglutamine-expanded huntingtin in Huntington's disease (HD) and mutant tau in fronto-temporal dementia/ tauopathy. Previously, we showed that rapamycin, an autophagy inducer, enhances mutant huntingtin fragment clearance and attenuated toxicity. Here we show much wider applications for this approach. Rapamycin enhances the autophagic clearance of different proteins with long polyglutamines and a polyalanine-expanded protein, and reduces their toxicity. Rapamycin also reduces toxicity in Drosophila expressing wild-type or mutant forms of tau and these effects can be accounted for by reductions in insoluble tau. Thus, our studies suggest that the scope for rapamycin as a potential therapeutic in aggregate diseases may be much broader than HD or even polyglutamine diseases. © The Author 2005. Published by Oxford University Press. All rights reserved.

Cite

CITATION STYLE

APA

Berger, Z., Ravikumar, B., Menzies, F. M., Oroz, L. G., Underwood, B. R., Pangalos, M. N., … Rubinsztein, D. C. (2006). Rapamycin alleviates toxicity of different aggregate-prone proteins. Human Molecular Genetics, 15(3), 433–442. https://doi.org/10.1093/hmg/ddi458

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free